[Anti-tumor vaccination].
Five year survival rates are presented for 32 primary operated breast cancer patients who were postoperatively treated with an optimal dose of autologous NDV-modified tumor vaccine. Their overall survival and their recurrent-free survival was significantly better than that of 31 comparable breast cancer patients treated simultaneously with a suboptimal dose of the same type of vaccine. The concept, development and mechanism of action of this vaccine are als commented on.